Biotech Drives Base Editing Into Clinic As Big Pharma Looks On
Executive Summary
Base editing has reached a new milestone as Beam’s lead candidate gets the green light for clinical trials, and its peer Verve Therapeutics is not far behind, while big pharma dips its toes in the water.
You may also be interested in...
Gene Editing Excels As Regenerative Medicine Reaches Record Investments
Gene and cell-based therapeutics attracted the bulk of regenerative medicine investment last year, with gene-editing approaches garnering confidence following key clinical milestones, new research shows.
Beam Anticipates Pfizer Deal Will Lead To Additional Partnerships
The $300m upfront payment should provide considerable runway for the base-editing company, which also plans multiple IND filings and enrolling the first patient in its sickle cell study this year.
Gene-Editing Companies To Watch At J.P. Morgan
Share prices for many gene-editing companies declined in 2021, but the field is burgeoning with novel approaches due to be highlighted at the J.P. Morgan meeting, and one player, Intellia, could move closer to a breakthrough in 2022.